MA51823A - Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules - Google Patents

Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules

Info

Publication number
MA51823A
MA51823A MA051823A MA51823A MA51823A MA 51823 A MA51823 A MA 51823A MA 051823 A MA051823 A MA 051823A MA 51823 A MA51823 A MA 51823A MA 51823 A MA51823 A MA 51823A
Authority
MA
Morocco
Prior art keywords
osimertinib
treatment
lung cancer
small cell
cell lung
Prior art date
Application number
MA051823A
Other languages
English (en)
Inventor
Anthony Francis Patrick Nash
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA51823A publication Critical patent/MA51823A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051823A 2018-02-12 2019-02-11 Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules MA51823A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862629166P 2018-02-12 2018-02-12

Publications (1)

Publication Number Publication Date
MA51823A true MA51823A (fr) 2021-05-19

Family

ID=65443828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051823A MA51823A (fr) 2018-02-12 2019-02-11 Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules

Country Status (15)

Country Link
US (4) US20200368231A1 (fr)
EP (2) EP4431154A3 (fr)
JP (2) JP2021513517A (fr)
KR (2) KR20200119243A (fr)
CN (2) CN116870008A (fr)
AU (2) AU2019219304A1 (fr)
BR (1) BR112020015507A2 (fr)
CA (1) CA3090010A1 (fr)
EA (1) EA202091841A1 (fr)
IL (1) IL276406A (fr)
MA (1) MA51823A (fr)
MX (1) MX2020008395A (fr)
SG (1) SG11202007414XA (fr)
TW (2) TWI868714B (fr)
WO (1) WO2019155059A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3133766A1 (fr) 2019-03-29 2020-10-08 Astrazeneca Ab Osimertinib destine a etre utilise dans le traitement du cancer du poumon non a petites cellules
CN110433296A (zh) * 2019-08-16 2019-11-12 哈尔滨医科大学 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用
WO2021148396A1 (fr) * 2020-01-20 2021-07-29 Astrazeneca Ab Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique pour le traitement du cancer
WO2022120197A1 (fr) * 2020-12-03 2022-06-09 Emory University Associations d'inhibiteurs du récepteur du facteur de croissance épidermique et d'inhibiteurs de protéines de liaison à un élément régulateur de stérols destinées à être utilisées dans des thérapies anticancéreuses
WO2022166794A1 (fr) * 2021-02-02 2022-08-11 贝达药业股份有限公司 Utilisation d'icotinib dans une thérapie adjuvante post-opératoire pour le cancer du poumon non à petites cellules
US20240226101A1 (en) * 2021-04-30 2024-07-11 Suzhou Puhe BioPharma Co., Ltd. Pyrimidinylaminobenzenes for lung cancer treatment
CN114917231A (zh) * 2022-05-27 2022-08-19 杭州师范大学 β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用
KR102899565B1 (ko) 2023-02-14 2025-12-11 박주현 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (fr) 2011-07-27 2023-01-18 Astrazeneca AB Composés de 2-(anilino 2,4,5-substitué)pyrimidine
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP3191523B1 (fr) * 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki)
WO2016164217A1 (fr) * 2015-04-09 2016-10-13 Clovis Oncology, Inc. Combinaisons thérapeutiques pour le traitement du cancer
WO2017164887A1 (fr) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Régime de dosage pulsé et procédés de traitement
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
US20200038398A1 (en) * 2017-03-10 2020-02-06 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Also Published As

Publication number Publication date
KR20200119243A (ko) 2020-10-19
JP2023116537A (ja) 2023-08-22
AU2022203007B2 (en) 2024-07-04
EA202091841A1 (ru) 2020-10-28
TW202412804A (zh) 2024-04-01
US20240156815A1 (en) 2024-05-16
WO2019155059A1 (fr) 2019-08-15
SG11202007414XA (en) 2020-09-29
US20230226059A1 (en) 2023-07-20
AU2022203007A1 (en) 2022-05-26
CN111683663A (zh) 2020-09-18
EP3752153A1 (fr) 2020-12-23
KR20260009945A (ko) 2026-01-20
EP4431154A3 (fr) 2024-12-11
US20220184076A1 (en) 2022-06-16
CA3090010A1 (fr) 2019-08-15
MX2020008395A (es) 2020-09-21
BR112020015507A2 (pt) 2021-01-26
TWI868714B (zh) 2025-01-01
US20200368231A1 (en) 2020-11-26
JP2021513517A (ja) 2021-05-27
IL276406A (en) 2020-09-30
EP4431154A2 (fr) 2024-09-18
TW201941773A (zh) 2019-11-01
CN116870008A (zh) 2023-10-13
AU2019219304A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MA51823A (fr) Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
MA55508A (fr) Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
DK3849534T3 (da) Kombination af dasatinib og adagrasib til anvendelse i behandling af ikke-småcellet lungecancer
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
EP3631846A4 (fr) Mandrin électrostatique destiné à être utilisé dans le traitement de semi-conducteur
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
MA44119A (fr) Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale
EP3624896A4 (fr) Compositions et procédés pour le traitement du cancer avec mutations de braf atypiques
MA51762A (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc et d'autres cancers
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
EP3471717A4 (fr) Traitement des carcinomes à cellules squameuses à l'aide d'inhibiteurs d'erk
EP3796920A4 (fr) Compositions d'arnt/pré-miarn et leur utilisation dans le traitement du cancer
EP3288957A4 (fr) Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
EP3801563A4 (fr) Matériels et procédés de traitement du cancer
EP3813870C0 (fr) Inhibiteur de ccr5 destiné à être utilisé dans le traitement du cancer
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
EP3678692A4 (fr) Stratification du génotype dans le traitement et la prévention du diabète
MA47458A (fr) Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
MA51821A (fr) Inhibiteurs de la thiorédoxine réductase à utiliser dans le traitement du cancer